These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 25039448)

  • 21. Comparison of insulin lispro protamine suspension and insulin detemir in basal-bolus therapy in patients with Type 1 diabetes.
    Chacra AR; Kipnes M; Ilag LL; Sarwat S; Giaconia J; Chan J;
    Diabet Med; 2010 May; 27(5):563-9. PubMed ID: 20536953
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT).
    Le Floch JP; Lévy M; Mosnier-Pudar H; Nobels F; Laroche S; Gonbert S; Eschwege E; Fontaine P;
    Diabetes Care; 2009 Jan; 32(1):32-7. PubMed ID: 18945928
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes.
    Borah BJ; Darkow T; Bouchard J; Aagren M; Forma F; Alemayehu B
    Clin Ther; 2009 Mar; 31(3):623-31. PubMed ID: 19393853
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial.
    Miser WF; Arakaki R; Jiang H; Scism-Bacon J; Anderson PW; Fahrbach JL
    Clin Ther; 2010 May; 32(5):896-908. PubMed ID: 20685497
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Daily insulin doses and injection frequencies of neutral protamine hagedorn (NPH) insulin, insulin detemir and insulin glargine in type 1 and type 2 diabetes: a multicenter analysis of 51 964 patients from the German/Austrian DPV-wiss database.
    Laubner K; Molz K; Kerner W; Karges W; Lang W; Dapp A; Schütt M; Best F; Seufert J; Holl RW
    Diabetes Metab Res Rev; 2014 Jul; 30(5):395-404. PubMed ID: 24302583
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decrease in clinical hypoglycemia in young children with type 1 diabetes treated with free-mixed aspart and detemir insulin: an open labeled randomized trial.
    Petit-Bibal C; Rothenbuhler A; Lucchini P; Aboumrad B; Castell AL; Le Fur S; Bougnères P
    Pediatr Diabetes; 2015 Aug; 16(5):345-53. PubMed ID: 24888575
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy.
    Pieber TR; Treichel HC; Hompesch B; Philotheou A; Mordhorst L; Gall MA; Robertson LI
    Diabet Med; 2007 Jun; 24(6):635-42. PubMed ID: 17381500
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes.
    Meneghini L; Kesavadev J; Demissie M; Nazeri A; Hollander P
    Diabetes Obes Metab; 2013 Aug; 15(8):729-36. PubMed ID: 23421331
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes.
    Rosenstock J; Davies M; Home PD; Larsen J; Koenen C; Schernthaner G
    Diabetologia; 2008 Mar; 51(3):408-16. PubMed ID: 18204830
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Flexible insulin therapy with glargine insulin improved glycemic control and reduced severe hypoglycemia among preschool-aged children with type 1 diabetes mellitus.
    Alemzadeh R; Berhe T; Wyatt DT
    Pediatrics; 2005 May; 115(5):1320-4. PubMed ID: 15867042
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Twice- rather than once-daily basal insulin is associated with better glycaemic control in Type 1 diabetes mellitus 12 months after skills-based structured education in insulin self-management.
    Hopkinson HE; Jacques RM; Gardner KJ; Amiel SA; Mansell P
    Diabet Med; 2015 Aug; 32(8):1071-6. PubMed ID: 25982032
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detemir vs Glargine: Comparison of Inpatient Glycemic Control.
    Capson J; Cade K; Avanesyan A
    J Am Osteopath Assoc; 2019 Feb; 119(2):89-95. PubMed ID: 30688354
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment persistence after initiating basal insulin in type 2 diabetes patients: A primary care database analysis.
    Pscherer S; Chou E; Dippel FW; Rathmann W; Kostev K
    Prim Care Diabetes; 2015 Oct; 9(5):377-84. PubMed ID: 25701545
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship of insulin dose, A1c lowering, and weight in type 2 diabetes: comparing insulin glargine and insulin detemir.
    Dailey G; Admane K; Mercier F; Owens D
    Diabetes Technol Ther; 2010 Dec; 12(12):1019-27. PubMed ID: 21128849
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.
    Ilag LL; Kerr L; Malone JK; Tan MH
    Clin Ther; 2007 Jun; 29(6 Pt 1):1254-70. PubMed ID: 18036388
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of insulin detemir and insulin glargine on glycemic variability in patients with type 1 and type 2 diabetes.
    Tone A; Iseda I; Higuchi C; Tsukamoto K; Katayama A; Matsushita Y; Hida K; Wada J; Shikata K
    Exp Clin Endocrinol Diabetes; 2010 May; 118(5):320-4. PubMed ID: 20072962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Much ado about nothing? A real-world study of patients with type 2 diabetes switching Basal insulin analogs.
    Wei W; Zhou S; Miao R; Pan C; Xie L; Baser O; Gill J
    Adv Ther; 2014 May; 31(5):539-60. PubMed ID: 24831915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study.
    Dornhorst A; Lüddeke HJ; Honka M; Ackermann RW; Meriläinen M; Gallwitz B; Sreenan S;
    Curr Med Res Opin; 2008 Feb; 24(2):369-76. PubMed ID: 18096110
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison between a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) using continuous glucose monitoring in metabolically optimized type 1 diabetes patients: A randomized open-labelled parallel study.
    Ruiz-de-Adana MS; Dominguez-Lopez ME; Gonzalez-Molero I; Machado A; Martin V; Cardona I; de-la-Higuera M; Tapia MJ; Soriguer F; Anarte MT; Rojo-Martínez G
    Med Clin (Barc); 2016 Mar; 146(6):239-46. PubMed ID: 26656958
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of switching from first-generation basal insulin to Glargine 300 U/mL in children and adolescents with type 1 diabetes: results from the ISPED CARD database.
    Rossi MC; Bonfanti R; Graziano G; Larosa M; Lombardo F; Nicolucci A; Vespasiani G; Zucchini S; Rabbone I;
    Acta Diabetol; 2024 Sep; 61(9):1169-1176. PubMed ID: 38789610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.